Correction to: The role of p53 status on the synergistic effect of CKD-602 and cisplatin on oral squamous cell carcinoma cell lines

Hyeong Sim Choi¹ · Young-Kyun Kim¹ · Pil-Young Yun¹

Published online: 24 August 2021
© Springer Nature B.V. 2021

Correction to: Molecular Biology Reports (2019) 46:617–625
<https://doi.org/10.1007/s11033-018-4517-9>

In the original publication of this article, the Figure legends were incorrectly updated and the revised Figure legends are given below:

Fig. 1 Proliferation of OSCC cancer cells is inhibited by CKD-602 (0.1 µg/mL) with cisplatin for 24 h. The effect of CKD-602 with or without cisplatin on the viability in **a** YD-8, **c** YD-9, and **e** YD-38 cells was determined by MTT assay (mean ± SD; $n = 6$). * $p < 0.05$ versus only cisplatin-treated cells. **b**, **d**, and **f** A fraction affected versus CI plot (cisplatin/CKD-602) was determined by the method of Chou-Talalay and CompuSyn software

Fig. 2 CKD-602 (0.1 µg/mL) combination with cisplatin (5 or 10 µg/mL) induces cell death in OSCC cancer cell lines for 24 h. **a–c** Left panel, the cytotoxic effect of CKD-602 with and without cisplatin in YD-8 (**a**), YD-9 (**b**), and YD-38 (**c**) cells was determined by PI staining assay. Right panel, data represent quantitative results for left panel (mean ± SD; $n = 3$). * $p < 0.05$ versus only cisplatin-treated cells and ** $p < 0.05$ versus only CKD-602-treated cells

Fig. 3 CKD-602 (0.1 µg/mL) triggers chemosensitivity of cisplatin (5 or 10 µg/mL) in OSCC cancer cells. **a–c** Left panel, the apoptotic cell death of CKD-602 combination

with cisplatin in YD-8 (**a**), YD-9 (**b**), and YD-38 (**c**) cells for 24 h were determined by FACS analysis. The dead cells were differentiated between apoptosis and necrosis by Annexin V-FITC and 7-AAD dual staining. Right panel, data represent quantitative results for Annexin V positive cells of left panel (mean ± SD; $n = 3$). * $p < 0.05$ versus only cisplatin-treated cells and ** $p < 0.05$ versus only CKD-602-treated cells

Fig. 4 CKD-602 (0.1 µg/mL) combination with cisplatin (5 or 10 µg/mL) induces apoptosis in OSCC cancer cell lines for 24 h. **a** The expression of p53, Bax, Bcl-2, cleaved-caspase-9, -3, -7, and PARP in cell lysates from YD-8, YD-9, YD-38 cells treated with CKD-602 in presence and absence of cisplatin was determined by Western blot assay. **b** The Bax/Bcl-2 ratio was quantified using Image Lab Software (Bio-Rad, Hercules, CA, USA). **c** Schematic diagram showing that CKD-602 enhances cisplatin-mediated apoptosis in OSCC cancer cell lines

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s11033-018-4517-9>.

✉ Pil-Young Yun
pilyoung@snubh.org
Hyeong Sim Choi
simmi0326@gmail.com
Young-Kyun Kim
kyk0505@snubh.org

¹ Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital, 82 Gumi-ro 173 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, South Korea